Lupus & antiphospholipid syndrome
Cardiac involvement in a Spanish unicentric prospective cohort of patients with systemic lupus erythematosus
Authors' conclusion
Cardiac involvement in SLE is diverse, heterogeneous, and highly prevalent. Presenting a pathological TTE was associated with greater damage accrual and greater mortality.
Study context
- Population
- Patients with Systemic Lupus Erythematosus (SLE) meeting the 2019 EULAR/ACR classification criteria who underwent TTE, Spanish Lupus Clinic
- Participants
- 201 patients
- Outcome
- Prevalence of cardiac involvement
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Cardiac involvement (prevalence)
Cardiac involvement present
43.8%
Observational data: associations, not effects.
Further findings
Risk factors for cardiac involvement
- Older age, hypertension, hyperlipidemia, higher BMI, peripheral arterial disease, thrombosis and major CV events: significantly more cardiac involvement
- Neurological, hematological and serosal involvement (pleuritis and/or pericarditis) were clinical risk factors for abnormal TTE
- Anti-B2GP1 was the only autoantibody associated with cardiac involvement
Combination of dyspnea, chest pain, cough and/or syncope in patients with abnormal TTE in follow-up
- Present in patients with abnormal TTE; superior to each manifestation separately
- 40.9%
Biomarkers
- Troponin I (TnI) ≥ 0.2 ng/mL and NTproBNP ≥ 300 pg/mL: excellent biomarkers with good correlation with cardiac abnormalities
Damage and mortality · 2-year follow-up
- Cardiac involvement correlated with higher SLICC Damage Index and increased mortality risk
Original publication
Cardiac involvement in a Spanish unicentric prospective cohort of patients with systemic lupus erythematosus. Lupus. Published 22 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →